APHEXDA motixafortide
莫替沙福肽
Drug Class
CXCR4 antagonistCXCR4 拮抗剂
Mechanism
Inhibits CXCR4 binding to SDF-1alpha, mobilizing CD34+ hematopoietic stem cells from bone marrow to peripheral blood.抑制 CXCR4 与 SDF-1α 的结合，从而将 CD34+ 造血干细胞从骨髓动员至外周血中。
Approved Indication
In combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with multiple myeloma.联合菲格司亭 (G-CSF) 动员造血干细胞进入外周血，以在多发性骨髓瘤患者中进行采集并随后进行自体干细胞移植。
What This Means For Patients
APHEXDA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.APHEXDA（莫替沙福肽）目前未通过中国大陆零售药房渠道销售。优健云可协助安排购买渠道，药品由香港采购发货；如有需要，可协调来华后的临床用药支持。具体供应及患者适用性以医疗预检评估为准。
Regulatory Approvals
- FDA — Approved (2023) — Sources
Pivotal Clinical Evidence
- GENESIS — Crees et al., Nat Med 2023 (NCT03246529) — Sources